JP2009544618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544618A5 JP2009544618A5 JP2009520862A JP2009520862A JP2009544618A5 JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5 JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aliphatic
- ring
- optionally substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 Chemical compound CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 0.000 description 73
- YMQLSSLCXRWKQA-UHFFFAOYSA-O CC(C(N1)=O)(NC1=O)[IH+] Chemical compound CC(C(N1)=O)(NC1=O)[IH+] YMQLSSLCXRWKQA-UHFFFAOYSA-O 0.000 description 3
- SWFZYGSTUWMTPI-UHFFFAOYSA-N CC(C)(C=CN1)C1=O Chemical compound CC(C)(C=CN1)C1=O SWFZYGSTUWMTPI-UHFFFAOYSA-N 0.000 description 3
- BTJMCRAWBQGQIK-UHFFFAOYSA-N CC(C)(c(ccnc1)c1N1)C1=O Chemical compound CC(C)(c(ccnc1)c1N1)C1=O BTJMCRAWBQGQIK-UHFFFAOYSA-N 0.000 description 3
- FWWMMGOPZBVMNB-UHFFFAOYSA-N CC(C)(c(nccc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(nccc1)c1N1)/C1=[O]\C FWWMMGOPZBVMNB-UHFFFAOYSA-N 0.000 description 3
- CZGJOXNVXIVFAV-UHFFFAOYSA-N CC(C)(c(ncnc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(ncnc1)c1N1)/C1=[O]\C CZGJOXNVXIVFAV-UHFFFAOYSA-N 0.000 description 3
- OISPDNWOHCABMC-UHFFFAOYSA-N CC(C)C(C)(C1C(N2)OCCC1)C2=O Chemical compound CC(C)C(C)(C1C(N2)OCCC1)C2=O OISPDNWOHCABMC-UHFFFAOYSA-N 0.000 description 3
- SHAYFAIWNAOVSE-UHFFFAOYSA-N CC(C)C(C)(c1c(N2)nc[s]1)C2=O Chemical compound CC(C)C(C)(c1c(N2)nc[s]1)C2=O SHAYFAIWNAOVSE-UHFFFAOYSA-N 0.000 description 3
- QGECDFDEEKEVJO-UHFFFAOYSA-N CC(C)C(C)(c1cccnc1N1)C1=O Chemical compound CC(C)C(C)(c1cccnc1N1)C1=O QGECDFDEEKEVJO-UHFFFAOYSA-N 0.000 description 3
- SXVJIQFQZNOJAX-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[IH]C Chemical compound CC(C)C(CC(N1)=O)(C1=O)[IH]C SXVJIQFQZNOJAX-UHFFFAOYSA-N 0.000 description 3
- WWFBWCVOVMKUCZ-UHFFFAOYSA-O CC(C1=C(N2)OCC1)(C2=O)[IH+] Chemical compound CC(C1=C(N2)OCC1)(C2=O)[IH+] WWFBWCVOVMKUCZ-UHFFFAOYSA-O 0.000 description 3
- FHDPJMNNOTUEKT-UHFFFAOYSA-N CC(C1=C(N2)OCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)OCCC1)(C2=O)[IH]I FHDPJMNNOTUEKT-UHFFFAOYSA-N 0.000 description 3
- LVQDZEAOMZKSMI-UHFFFAOYSA-N CC(C1=C(N2)SCC1)(C2=O)I Chemical compound CC(C1=C(N2)SCC1)(C2=O)I LVQDZEAOMZKSMI-UHFFFAOYSA-N 0.000 description 3
- OYOMJOLPSFPIBL-UHFFFAOYSA-N CC(C1C(N2)SCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)SCC1)(C2=O)[IH]C OYOMJOLPSFPIBL-UHFFFAOYSA-N 0.000 description 3
- DQFMPTUTAAIXAN-UHFFFAOYSA-N CC1(C)N=CNC1=O Chemical compound CC1(C)N=CNC1=O DQFMPTUTAAIXAN-UHFFFAOYSA-N 0.000 description 3
- CEDXQSMKYRXVHU-UHFFFAOYSA-N C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C Chemical compound C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C CEDXQSMKYRXVHU-UHFFFAOYSA-N 0.000 description 3
- DFIMFVQCVXMERG-UHFFFAOYSA-N O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 Chemical compound O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 DFIMFVQCVXMERG-UHFFFAOYSA-N 0.000 description 3
- BDEDPOLWMVWPSK-UHFFFAOYSA-N CC(C)(c1c(N2)nc[nH]1)C2=O Chemical compound CC(C)(c1c(N2)nc[nH]1)C2=O BDEDPOLWMVWPSK-UHFFFAOYSA-N 0.000 description 2
- FRUIAUUIOLTTEA-UHFFFAOYSA-N CC(C)(c1c(N2)nc[o]1)C2=O Chemical compound CC(C)(c1c(N2)nc[o]1)C2=O FRUIAUUIOLTTEA-UHFFFAOYSA-N 0.000 description 2
- FMYHJHHHIIJHRN-UHFFFAOYSA-N CC(C)C(C)(c(nccc1)c1N1)C1=O Chemical compound CC(C)C(C)(c(nccc1)c1N1)C1=O FMYHJHHHIIJHRN-UHFFFAOYSA-N 0.000 description 2
- NSEAPTQEZZLMKF-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[I](C)I Chemical compound CC(C)C(CC(N1)=O)(C1=O)[I](C)I NSEAPTQEZZLMKF-UHFFFAOYSA-N 0.000 description 2
- RNWFHTNSACTMTG-UHFFFAOYSA-N CC(C)C1(C(C)I)N=CNC1=O Chemical compound CC(C)C1(C(C)I)N=CNC1=O RNWFHTNSACTMTG-UHFFFAOYSA-N 0.000 description 2
- CYKTWUBYWZXJSX-UHFFFAOYSA-N CC(C1=C(N2)SCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)SCCC1)(C2=O)[IH]I CYKTWUBYWZXJSX-UHFFFAOYSA-N 0.000 description 2
- VHNASZIROAFYSA-UHFFFAOYSA-O CC(C1C(N2)OCC1)(C2=O)[IH+](C)C Chemical compound CC(C1C(N2)OCC1)(C2=O)[IH+](C)C VHNASZIROAFYSA-UHFFFAOYSA-O 0.000 description 2
- LBHWSNRLSIZGPI-UHFFFAOYSA-N CC(C1C(N2)OCCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)OCCC1)(C2=O)[IH]C LBHWSNRLSIZGPI-UHFFFAOYSA-N 0.000 description 2
- VFJSJACITUAVID-UHFFFAOYSA-N CC(C=CN1)(C1=O)[IH]I Chemical compound CC(C=CN1)(C1=O)[IH]I VFJSJACITUAVID-UHFFFAOYSA-N 0.000 description 2
- IJUNQHFGBLBXBB-UHFFFAOYSA-N CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C Chemical compound CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C IJUNQHFGBLBXBB-UHFFFAOYSA-N 0.000 description 2
- BNMHGYUQURKKHB-UHFFFAOYSA-N C[IH]C1=[O][IH]c(ccnc2)c2N1 Chemical compound C[IH]C1=[O][IH]c(ccnc2)c2N1 BNMHGYUQURKKHB-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83239706P | 2006-07-21 | 2006-07-21 | |
| US60/832,397 | 2006-07-21 | ||
| PCT/US2007/016559 WO2008011190A1 (en) | 2006-07-21 | 2007-07-23 | Cgrp receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544618A JP2009544618A (ja) | 2009-12-17 |
| JP2009544618A5 true JP2009544618A5 (OSRAM) | 2011-08-18 |
| JP5511379B2 JP5511379B2 (ja) | 2014-06-04 |
Family
ID=38754729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520862A Expired - Fee Related JP5511379B2 (ja) | 2006-07-21 | 2007-07-23 | Ｃｇｒｐレセプターアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7842686B2 (OSRAM) |
| EP (1) | EP2049532B1 (OSRAM) |
| JP (1) | JP5511379B2 (OSRAM) |
| CN (1) | CN101516875A (OSRAM) |
| AT (1) | ATE469895T1 (OSRAM) |
| AU (1) | AU2007275577A1 (OSRAM) |
| CA (1) | CA2658573A1 (OSRAM) |
| DE (1) | DE602007006961D1 (OSRAM) |
| ES (1) | ES2343481T3 (OSRAM) |
| WO (1) | WO2008011190A1 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080068062A (ko) | 2005-11-14 | 2008-07-22 | 리나트 뉴로사이언스 코퍼레이션 | 칼시토닌 유전자-관련 펩티드에 대해 지시되는 길항제 항체및 그의 사용 방법 |
| WO2007133491A1 (en) | 2006-05-09 | 2007-11-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| CA2714985C (en) | 2008-01-07 | 2018-05-15 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| ES2689322T3 (es) * | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| BRPI0908276B8 (pt) | 2008-03-04 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite |
| EP2271346B1 (en) * | 2008-03-28 | 2014-01-01 | Merck Sharp & Dohme Corp. | Monocyclic cgrp receptor antagonists |
| US8362005B2 (en) * | 2008-09-08 | 2013-01-29 | Merk. Sharp & Dohme Corp. | Monocyclic amide CGRP receptor antagonists |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| RU2535074C2 (ru) | 2009-08-28 | 2014-12-10 | Лэйбрис Байолоджикс, Инк. | Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина |
| SG194973A1 (en) | 2011-05-20 | 2013-12-30 | Alderbio Holdings Llc | Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| US9745373B2 (en) | 2011-05-20 | 2017-08-29 | Alderbio Holdings Llc | Anti-CGRP compositions and use thereof |
| CA2888816A1 (en) * | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| CR20160553A (es) | 2014-04-30 | 2017-04-25 | Incyte Corp | Procesos para preparar un inhibidor de jak1 y nuevas formas de este |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| MX380753B (es) | 2015-07-02 | 2025-04-01 | Hoffmann La Roche | Lactamas bicíclicas y métodos de uso de las mismas. |
| EA201891620A1 (ru) | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN112423759A (zh) | 2018-03-30 | 2021-02-26 | 因赛特公司 | 使用jak抑制剂治疗化脓性汗腺炎 |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| AU2020206241A1 (en) | 2019-01-08 | 2021-08-26 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| MX2024008648A (es) | 2022-01-12 | 2024-09-23 | Denali Therapeutics Inc | Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida. |
| AU2023207658A1 (en) * | 2022-01-14 | 2024-08-29 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1606264B1 (en) * | 2003-03-14 | 2012-05-02 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirohydantoin cgrp receptor antagonists |
| AU2004222328B2 (en) * | 2003-03-14 | 2009-10-08 | Merck Sharp & Dohme Corp. | Aryl spirohydantoin CGRP receptor antagonists |
| CA2519475A1 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin cgrp receptor antagonists |
| CA2519515A1 (en) * | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| US7288559B2 (en) * | 2003-03-14 | 2007-10-30 | Merck + Co, Inc. | Carboxamide spirohydantoin CGRP receptor antagonists |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| AU2005285083B2 (en) * | 2004-09-13 | 2011-03-10 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantoin CGRP receptor antagonists |
| WO2006031610A2 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| CN101072771B (zh) * | 2004-10-07 | 2010-09-29 | 默沙东公司 | Cgrp受体拮抗剂 |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
-
2007
- 2007-07-23 ES ES07796984T patent/ES2343481T3/es active Active
- 2007-07-23 DE DE602007006961T patent/DE602007006961D1/de active Active
- 2007-07-23 AU AU2007275577A patent/AU2007275577A1/en not_active Abandoned
- 2007-07-23 EP EP07796984A patent/EP2049532B1/en not_active Not-in-force
- 2007-07-23 CA CA002658573A patent/CA2658573A1/en not_active Abandoned
- 2007-07-23 WO PCT/US2007/016559 patent/WO2008011190A1/en not_active Ceased
- 2007-07-23 CN CNA2007800342187A patent/CN101516875A/zh active Pending
- 2007-07-23 JP JP2009520862A patent/JP5511379B2/ja not_active Expired - Fee Related
- 2007-07-23 AT AT07796984T patent/ATE469895T1/de not_active IP Right Cessation
-
2009
- 2009-01-21 US US12/356,745 patent/US7842686B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544618A5 (OSRAM) | ||
| JP7664947B2 (ja) | Ｉｌ－１７の調節因子としてのイミダゾリダジン | |
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP7331843B2 (ja) | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 | |
| KR20230026404A (ko) | Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드 | |
| CA3121719A1 (en) | Amino-acid anilides as small molecule modulators of il-17 | |
| US20220380338A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| JP2016516043A5 (OSRAM) | ||
| JP2011523412A5 (OSRAM) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| TW200305425A (en) | 8-Azaprostaglandin derivatives and medicament containing same as active ingredient | |
| JP2012517446A (ja) | Ｓ１ｐ５受容体の作動薬および拮抗薬ならびにそれらの使用方法 | |
| BR112020008850A2 (pt) | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 | |
| CA3075669A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| AU2009298617A1 (en) | Spiro-imidazolone derivatives as glucagon receptor antagonists | |
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| UA128085C2 (uk) | ТРЕТИННІ СПИРТИ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> | |
| CA3075705A1 (en) | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | |
| UA128288C2 (uk) | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> | |
| CA3173777A1 (en) | Inhibitors and degraders of pip4k protein | |
| JP2017538753A5 (OSRAM) | ||
| CA2948543A1 (en) | Carboxamide derivatives | |
| KR20110044947A (ko) | 과잉활성 면역계 치료를 위한 사이클로리그난의 용도 | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты |